Sign in to view content

Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial

Dante Joseph Pieramici, MD

Video
Published 2021

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
Impact of Delayed Treatment in Diabetic Retinal Disease: Experience From VISTA/VIVID and PANORAMA
Sunil Srivastava, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more